Clearmind Medicine Inc. Common Shares - Asset Resilience Ratio
Clearmind Medicine Inc. Common Shares (CMND) has an Asset Resilience Ratio of 9.78% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CMND net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Clearmind Medicine Inc. Common Shares's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Clearmind Medicine Inc. Common Shares total assets.
Liquid Assets Composition Over Time
This chart breaks down Clearmind Medicine Inc. Common Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Clearmind Medicine Inc. Common Shares balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.09 Million | 9.78% |
| Total Liquid Assets | $1.09 Million | 9.78% |
Asset Resilience Insights
- Limited Liquidity: Clearmind Medicine Inc. Common Shares maintains only 9.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Clearmind Medicine Inc. Common Shares Industry Peers by Asset Resilience Ratio
Compare Clearmind Medicine Inc. Common Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Clearmind Medicine Inc. Common Shares (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Clearmind Medicine Inc. Common Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 27.33% | $1.66 Million | $6.08 Million | +23.34pp |
| 2024-10-31 | 3.99% | $402.83K | $10.10 Million | +2.54pp |
| 2023-10-31 | 1.45% | $86.11K | $5.95 Million | -22.00pp |
| 2022-10-31 | 23.44% | $262.98K | $1.12 Million | -- |
| 2021-10-31 | 0.00% | $0.00 | $4.16 Million | -- |
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It d… Read more